Sarepta reiterates $1.2B-$1.4B 2026 net product revenue guidance while targeting Cohort 8 data by year-end
Sarepta Therapeutics,, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $17.61
-18% in 7d after detection
Post-detection moves
1h
—
1d
-4.1%
3d
-8.0%
7d
-18%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS